Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, raised $50 million by offering 10 million shares at $5 after originally planning to sell 6 million shares at a range of $12-$14. Trius Therapeutics plans to list on the NASDAQ under the symbol TSRX. Citi, Piper Jaffray and Canaccord Genuity acted as lead managers on the deal.
